Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use

US9181198B2 · kind B2 · utility

Assignee

• Oryzon Genomics S.A. · ES

Inventors

• Alberto Ortega Muñoz · Barcelona, ES
• Matthew Colin Thor Fyfe · Chipping Norton, GB
• Marc Martinell Pedemonte · Barcelona, ES
• Inigo TIRAPU FERNANDEZ DE LA CUESTA · Barcelona, ES
• Maria de los Angeles Estiarte-Martinez · San Francisco, US

Key dates

• Filing date: Jul 27, 2011
• Grant date: Nov 10, 2015
• Expiry date: Feb 16, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D413/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection. Thus, in one specific aspect the invention relates to formulas (II), (III), (IV), (V), (VI), (VII), (VIII), (IX).